OncoNano Medicine Inc (OncoNano) is biotechnology company that develops pH-activated compounds that digitalize and exploit the variability of pH in disease. The company's pipeline products include ONM-501, ONM- 412 for the treatment of advanced or metastatic solid tumors and pegsitacianine targets peritoneal metastases multiple tumor types. It offers clinical trials. It markets its products under the brands OMNI and ON-BOARD. It utilizes ON-BOARD technology platform to discover drugs. It develops products in the therapeutic areas of cancer, alzheimer’s and metabolic disorders. OncoNano is headquartered in Southlake, Texas, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company OncoNano Medicine Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- OncoNano Medicine Inc Company Overview
- OncoNano Medicine Inc Company Snapshot
- OncoNano Medicine Inc Pipeline Products and Ongoing Clinical Trials Overview
- OncoNano Medicine Inc - Pipeline Analysis Overview
- OncoNano Medicine Inc - Key Facts
- OncoNano Medicine Inc - Major Products and Services
- OncoNano Medicine Inc Pipeline Products by Development Stage
- OncoNano Medicine Inc Ongoing Clinical Trials by Trial Status
- OncoNano Medicine Inc Pipeline Products Overview
- ONM-100
- ONM-100 Product Overview
- ONM-300
- ONM-300 Product Overview
- Pegsitacianine Intraoperative Imaging Agent
- Pegsitacianine Intraoperative Imaging Agent Product Overview
- Pegsitacianine Intraoperative Imaging Agent Clinical Trial
- OncoNano Medicine Inc - Key Competitors
- OncoNano Medicine Inc - Key Employees
- OncoNano Medicine Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- OncoNano Medicine Inc, Recent Developments
- Aug 25, 2023: AHN Cancer Institute Leads Clinical Trial of Fluorescent Agent That “Lights Up” Previously Undetectable Cancer Cells to Guide Surgical Resection
- May 31, 2023: OncoNano Medicine positivec final results from phase 2 trial of Pegsitacianine in Podium presentation at 2023 ASCO Annual Meeting
- Apr 27, 2023: OncoNano Medicine announces oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
- Mar 27, 2023: OncoNano Medicine presents data from phase 2 pegsitacianine study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care
- Jan 04, 2023: OncoNano Medicine’s Pegsitacianine granted breakthrough therapy designation for real-time surgical imaging by the Food and Drug Administration
- Nov 14, 2022: OncoNano Medicine Announces New Preclinical Data for ON-BOARD Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer Annual Meeting
- Sep 29, 2022: OncoNano Medicine announces positive phase 2 data for pegsitacianine as an adjunct to cytoreductive surgery of peritoneal carcinomatosis
- Sep 14, 2022: OncoNano Medicine announces oral presentation of phase 2 study data at the World Molecular Imaging Congress 2022
- Mar 10, 2022: OncoNano Medicine to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
- Mar 10, 2022: OncoNano Medicine to Present at the American Association for Cancer Research Annual Meeting 2022
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- OncoNano Medicine Inc Pipeline Products and Ongoing Clinical Trials Overview
- OncoNano Medicine Inc Pipeline Products by Equipment Type
- OncoNano Medicine Inc Pipeline Products by Indication
- OncoNano Medicine Inc Ongoing Clinical Trials by Trial Status
- OncoNano Medicine Inc, Key Facts
- OncoNano Medicine Inc, Major Products and Services
- OncoNano Medicine Inc Number of Pipeline Products by Development Stage
- OncoNano Medicine Inc Pipeline Products Summary by Development Stage
- OncoNano Medicine Inc Ongoing Clinical Trials by Trial Status
- OncoNano Medicine Inc Ongoing Clinical Trials Summary
- ONM-100 - Product Status
- ONM-100 - Product Description
- ONM-300 - Product Status
- ONM-300 - Product Description
- Pegsitacianine Intraoperative Imaging Agent - Product Status
- Pegsitacianine Intraoperative Imaging Agent - Product Description
- Pegsitacianine Intraoperative Imaging Agent - A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
- OncoNano Medicine Inc, Key Employees
- Glossary
- OncoNano Medicine Inc Pipeline Products by Equipment Type
- OncoNano Medicine Inc Pipeline Products by Development Stage
- OncoNano Medicine Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Prelude Therapeutics Inc
- Predictive Oncology Inc
- Santa Barbara Imaging Systems Inc
- Gritstone Bio Inc
- NeuroLogica Corp
- Champions Oncology Inc
- Atossa Therapeutics Inc
- Siemens Healthcare Diagnostics Inc
- Sensus Healthcare Inc
